（文章来源：每日经济新闻） 每经AI快讯，美丽田园医疗健康(02373.HK)尾盘涨超9%，截至发稿涨9.04%，报27.26港元，成交额 2066.32万港元。 ...

消息面上，美丽田园医疗健康披露，12月1日，公司自非执行董事李方雨处获悉，其通过LIFY Management Holdings Limited于公开市场收购41,500股公司股份。同时，12月1日，美丽田园医疗健康发 布股份回购公告。公司通过公开市场回购80,000股公司股份，总交易金额约200.1万港元，交易平均价约 每股25港元。 公司指，10月份以来，美丽田园积极进行股份回购。自10月15日至12月1日，公司累计回购775,000股股 份，总对价约2,269.3万港元。董事会相信，持续的回购举措彰显了管理层对企业长期发展的坚定信心， 并将助力集团提升资本市场价值与股东回报能力。 美丽田园医疗健康(02373)尾盘涨超9%，截至发稿，涨9.04%，报27.26港元，成交额2066.32万港元。 ...

智通财经APP获悉，美丽田园医疗健康(02373)尾盘涨超9%，截至发稿，涨9.04%，报27.26港元，成交 额2066.32万港元。 消息面上，美丽田园医疗健康披露，12月1日，公司自非执行董事李方雨处获悉，其通过LIFY Management Holdings Limited 于公开市场收购41,500股公司股份。同时，12月1日，美丽田园医疗健康 发布股份回购公告。公司通过公开市场回购80,000股公司股份，总交易金额约200.1万港元，交易平均价 约每股25港元。 公司指，10月份以来，美丽田园积极进行股份回购。自10月15日至12月1日，公司累计回购775,000股股 份，总对价约2,269.3万港元。董事会相信，持续的回购举措彰显了管理层对企业长期发展的坚定信心， 并将助力集团提升资本市场价值与股东回报能力。 ...

格隆汇12月1日丨美丽田园医疗健康(02373.HK)公告，公司非执行董事李方雨已知会公司，于2025年12 月1日，彼于公司已发行股本之权益已增加41,500股公司普通股，占截至本公告日期已发行股份总数约 0.02%。该等股份乃透过LIFY Management Holdings Limited于公开市场进行收购。增持股份彰显其对集 团未来发展前景的坚定信念与高度信心。 ...

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) announced a share buyback on December 1, 2023, spending HKD 2 million to repurchase 80,000 shares at a price range of HKD 24.6 to 25.34 per share [1] Summary by Category - **Company Actions** - The company executed a buyback of 80,000 shares at a total cost of HKD 2 million [1] - The repurchase price per share ranged from HKD 24.6 to 25.34 [1]

Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Ms. Li Fangyu, in the future development of the company through her acquisition of 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] Group 1: Share Acquisition - Ms. Li Fangyu increased her stake in the company by acquiring 41,500 ordinary shares through LIFY Management Holdings Limited in the open market [1] - The company repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Group 2: Management Confidence - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The board expresses confidence that the share repurchase demonstrates management's strong belief in the long-term value of the enterprise, which is beneficial for enhancing the company's market value and shareholder return capabilities [1] - The share repurchase aligns with the overall interests of the company and its shareholders [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份 ...

Core Viewpoint - The announcement highlights the confidence of the company's non-executive director, Li Fangyu, in the future development of the company through the acquisition of additional shares, indicating a positive outlook for the company's growth [1] Share Acquisition by Director - Li Fangyu has increased her stake in the company by acquiring 41,500 shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - The shares were purchased through LIFY Management Holdings Limited in the open market, reflecting her strong belief in the company's prospects [1] Share Buyback Program - The company has repurchased 80,000 shares on December 1, 2025, for a total consideration of approximately HKD 2.0008 million, with an average transaction price of about HKD 25.01 per share [1] - From October 15, 2025, to the announcement date, the company has repurchased a total of 775,000 shares at a total cost of approximately HKD 22.6932 million [1] Management's Perspective - The board of directors believes that the current share price does not reflect the intrinsic value of the shares and the actual business prospects of the company [1] - The share buyback is seen as a demonstration of management's confidence in the long-term value of the company, which is expected to enhance the capital market value and shareholder return capabilities [1] - The buyback aligns with the overall interests of the company and its shareholders [1]

Core Viewpoint - Meili Tianyuan Medical Health (02373.HK) has repurchased a total of 775,000 shares since October 15, 2025, with a total expenditure of approximately 22,693,170 HKD, indicating a strategic move to enhance shareholder value [1] Summary by Sections - **Share Repurchase Details** - On December 1, 2025, the company repurchased 80,000 shares at an average price of approximately 25.01 HKD per share, totaling around 200,000 HKD [1] - The total shares repurchased from October 15, 2025, to the announcement date amounts to 775,000 shares [1] - **Financial Implications** - The total expenditure for the repurchased shares is approximately 22,693,170 HKD, reflecting the company's commitment to returning capital to shareholders [1]

Core Viewpoint - The announcement highlights the increase in shareholding by non-executive director Li Fangyu, indicating strong confidence in the future development of the company [1] Summary by Relevant Sections - **Shareholding Increase**: Li Fangyu has informed the company of an increase of 41,500 shares in the company's ordinary shares, representing approximately 0.02% of the total issued shares as of the announcement date [1] - **Acquisition Method**: The shares were acquired through LIFY Management Holdings Limited in the open market [1] - **Confidence in Future**: The increase in shareholding reflects Li Fangyu's firm belief and high confidence in the group's future prospects [1]